proposed mechanistic market 0.853
gene:
NLRP3, CASP1, IL1B, PYCARDpathway: NLRP3 inflammasome activationdisease: neurodegenerationPathogenic gut bacteria prime peripheral macrophages through NLRP3 inflammasome activation, creating a systemic pro-inflammatory state that enhances neuroinflammation and dopaminergic neuron vulnerability. Selective inflammasome inhibitors combined with microbiome restoration could break this inflammatory cycle.
Scores
Composite
0.653
Confidence
0.900
Novelty
0.700
Feasibility
0.800
Impact
0.800
Mechanism
0.800
Druggability
0.900
Safety
0.600
Evidence
For (5)
- NLRP3 inflammasome in neuroinflammation and central nervous system diseases. [Cell Mol Immunol]
- Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke. [Cell Rep Med]
- NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING. [Proc Natl Acad Sci U S A]
- Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption. [J Neuroinflammation]
- Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition. [Front Immunol]
Against (3)
- MCC950/NLRP3 inhibition has strong preclinical rationale but translational pharmacology and safety limitations remain unresolved for chronic neurodegenerative use. [Pharmacol Rev]
- A Parkinson NLRP3 inhibitor study focused on anti-inflammatory biomarker effects rather than demonstrated disease modification, leaving the clinical impact of inflammasome blockade uncertain. [Mov Disord]
- Gut-inflammasome links are framed as axis-level physiology and pathology, but do not prove that bacterial inflammasome priming is the dominant driver of dopaminergic vulnerability. [Front Immunol]
Discussion
No comments yet — be the first.